Cartesian Therapeutics(RNAC)
FREDERICK, MD
BiotechnologyFocus: mRNA-Engineered Cell Therapy
Cartesian Therapeutics is a life sciences company focused on mRNA-Engineered Cell Therapy.
Gene TherapyCell Therapy
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
0
Pipeline & Clinical Trials
Descartes-15
Refractory Multiple MyelomaClinical Trials (1)
NCT06304636Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1Descartes-25
Multiple MyelomaClinical Trials (1)
NCT05113342Descartes-25 in Relapsed/Refractory Multiple Myeloma
Phase 1Descartes 30
Acute Respiratory Distress SyndromeClinical Trials (1)
NCT04524962Study of Descartes-30 in Acute Respiratory Distress Syndrome
Phase 1Descartes-11
Multiple MyelomaClinical Trials (1)
NCT03994705Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1Descartes-08
Multiple MyelomaClinical Trials (1)
NCT03448978Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
Phase 1Descartes-08
Childhood-onset Systemic Lupus ErythematousClinical Trials (1)
NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Phase 1/2Descartes-08
Antisynthetase SyndromeClinical Trials (1)
NCT07391605Descartes-08 in Autoantibody Myositis
Phase 2Descartes-08
Systemic Lupus Erythematosus (SLE)Clinical Trials (1)
NCT06038474Descartes-08 for Patients With Systemic Lupus Erythematosus
Phase 2Descartes 11
Multiple MyelomaClinical Trials (1)
NCT04436029Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Phase 2Descartes-08
Myasthenia Gravis, GeneralizedClinical Trials (1)
NCT04146051Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
Phase 2Descartes 08
Myeloma MultipleClinical Trials (1)
NCT04816526Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Phase 2Decartes-08
Myasthaenia GravisClinical Trials (1)
NCT06799247Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2013
Portfolio: 12 clinical trials
SEC Filings: 2 available
Financials (FY2025)
Revenue
$39M50%
R&D Spend
$45M(116%)37%
Net Income
-$77MCash
$213M